Form 3 Filing for Gwen Melincoff at Chemomab Therapeutics Ltd.

This filing reports a Form 3, which indicates initial beneficial ownership, for Gwen Melincoff, a director at Chemomab Therapeutics Ltd. (CMMB). The report covers the period ending June 1, 2026. Melincoff was granted a stock option to buy American Depositary Shares (ADS) with an exercise price of $1.86 per share. The option has an exercise date of June 1, 2026, and an expiration date of June 1, 2036. This option represents the right to acquire 8,621 underlying ADSs. According to footnote F1, the option vests and becomes exercisable in equal monthly installments over a 36-month period, commencing on June 1, 2026. The ownership is reported as direct.